Current approaches to the treatment of Candida albicans infections

Bibliography

• MUNOZ P, BURILLO A, BOUZA E: Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int. J. Antimicrob. Agents (2000) 15:83–90.
   PubMed Web of Science ®Google Scholar
• ••Good review of the use of azoles to treat candidiasis.
   Google Scholar
• FRASER VJ, JONES M, DUNKEL J, STORFER S, MEDOFF G, DUNAGAN WC: Candidemia in a tertiary care hospital: epidemiology, risk factors and predictors of mortality[see comments].Clin. Infect. Dis. (1992) 15:414–421.
   PubMed Web of Science ®Google Scholar
• NOLLA-SALAS J, SITGES-SERRA A, LEON-GIL C et al.:Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med. (1997) 23:23–30.
   PubMed Web of Science ®Google Scholar
• WENZEL RP: Nosocomial candidemia: risk factors andattributable mortality. Clin. Infect. Dis. (19 9 5) 20:1531-1534.
   Google Scholar
• GROSSI P, FARINA C, FIOCCHI R, DALLA GASPERINA D: Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation (2000) 70:112–116.
   Google Scholar
• WHITE TC, MARR KA, BOWDEN RA: Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin. Mkrobiol. Rev. (1998) 11:382–402.
   PubMed Web of Science ®Google Scholar
• •Good review of the mechanisms of antifungal resistance.
   Google Scholar
• PERFECT JR, LINDSAY MH, DREW RH: Adverse drug reactions to systemic antifungals. Prevention and management. Drug Safe. (1992) 7:323–363.
   PubMed Web of Science ®Google Scholar
• WHITE TC: The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans.Antimicrob. Agents Chemother. (1997) 41:1488–1494.
   PubMed Web of Science ®Google Scholar
• WHITE TC: Increased mRNA levels of ERG16, CDR andMDR1 correlate with increases in azole resistance in Candida albicansisolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. (1997) 41:1482–1487.
   PubMed Web of Science ®Google Scholar
• VANDEN BOSSCHE H, MARICHAL P, ODDS FC: Molecular mechanisms of drug resistance in fungi. Trends Microbic)]. (1994) 2:393–400.
   PubMedGoogle Scholar
• HITCHCOCK CA: Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albkans and its interaction with azole antifungals. Biochem. Soc. Trans. (1991) 19:782–787.
   PubMed Web of Science ®Google Scholar
• KELLY SL, LAMB DC, BALDWIN BC, CORRAN AJ, KELLY DE: Characterization of Saccharomyces cerevisiae CYP61, sterol delta22-desaturase and inhibition by azole antifungal agents. J. Biol. Chem. (1997) 272:9986–9988.
   PubMed Web of Science ®Google Scholar
• KELLY SL, LAMB DC, KELLY DE: Sterol 22-desaturase, cytochrome P45061, possesses activity in xenobiotic metabolism. FEBS Lett. (1997) 412:233–235.
   PubMed Web of Science ®Google Scholar
• FAVRE B, RYDER NS: Characterization of squalene epoxidase activity from the dermatophyte Tricho-phyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob. Agents Chemother. (1996) 40:443–447.
   PubMed Web of Science ®Google Scholar
• VANDEN BOSSCHE H, WILLEMSENS G, MARICHAL P: Anti-Candida drugs-the biochemical basis for their activity. Grit. Rev. Microbic)]. (1987) 15:57–72.
   PubMed Web of Science ®Google Scholar
• ••Describes the mode of action for azoles and polyenes.
   Google Scholar
• JOSEPH-HORNE T, HOLLOMON DW: Molecular mechanisms of azole resistance in fungi. FEMS Microbic)]. Lett. (1997) 1 4 9:141–149.
   Google Scholar
• ••Review of azoles resistance.
   Google Scholar
• MULLER FM, LYMAN CA, WALSH TJ: Antimicrobial peptides as potential new antifungals. Mycoses (1999) 42:77–82.
   Web of Science ®Google Scholar
• ••Discussion of the use of antimicrobial peptides.
   Google Scholar
• ONISHI J, MEINZ M, THOMPSON J et al.: Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibi-tors. Antimicrob. Agents Chemother. (2000) 44:368–377.
   PubMed Web of Science ®Google Scholar
• ••Discussion of the use of glucan synthase inhibitors.
   Google Scholar
• MIZUTANI S, ENDO M, INO-UE T et al.: Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections. Antimicrob. Agents Chemother. (2000) 44:243–247.
   PubMed Web of Science ®Google Scholar
• ••Discussion of Candida vaccines.
   Google Scholar
• WAGNER RD, PIERSON C, WARNER T, DOHNALEK M, HILTY M, BALISH E: Probiotic effects of feeding heat-killed lactobacillus acidophilus and Lactoba-cillus casei to Candida albicans-colonized immunode-ficient mice. J. Food Prot. (2000) 63:638–644.
   PubMed Web of Science ®Google Scholar
• ••Discussion of probiotic therapy.
   Google Scholar
• MULLER FM, GROLL AH, WALSH TJ: Current approachesto diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus. Eur. j Pediatr. (1999) 158:187–199.
   PubMed Web of Science ®Google Scholar
• PARK IY, PARK CB, KIM MS, KIM SC: Parasin I, an antimi-crobial peptide derived from histone H2A in the catfish, Parasilurus asotus. FEBS Lett. (19 9 8) 437:258–262.
   Google Scholar
• CHEN J, FALLA TJ, LIU H et al.: Development ofprotegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers (2000) 55:88–98.
   PubMed Web of Science ®Google Scholar
• ABRUZZO GK, FLATTERY AM, GILL CJ et al: Evaluation ofthe echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergil-losis, candidiasis and cryp to co cco sis. Antimicrob. Agents Chemother. (1997) 41:2333–2338.
   PubMed Web of Science ®Google Scholar
• ABRUZZO GK, GILL CJ, FLATTERY AM et al.: Efficacy ofthe echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. (2000) 44:2310–8.
   PubMed Web of Science ®Google Scholar
• HANCOCK RE: Cationic antimicrobial peptides:towards clinical applications [In Process Citation]. Exp. Opin. Invest. Drugs (2000) 9:1723–1729.
   PubMed Web of Science ®Google Scholar
• DEL BRUTTO OH: [Central nervous system mycoticinfections]. Rev .Neurol. (2000) 30:447–459.
   PubMed Web of Science ®Google Scholar
• WU X, WILCOX CB, DEVASAHAYAM G et al.: The Esslprolyl isomerase is linked to chromatin remodeling complexes and the general transcription machinery. Embo (2000) 19:3727–3738.
   PubMed Web of Science ®Google Scholar
• BRAUN BR, HEAD WS, WANG MX, JOHNSON AD: Identifi- cation and characterization of TUP1-regulated genes in Candida albicans. Genetics (2000) 156:31–44.
   PubMed Web of Science ®Google Scholar
• KUIPERS ME, DE VRIES HG, EIKELBOOM MC, MEIJER DK, SWART PJ: Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob. Agents Chemother. (1999) 43:2635–2641.
   PubMed Web of Science ®Google Scholar
• MAESAKI S, HOSSAIN MA, MIYAZAKI Y, TOMONO K, TASHIRO T, KOHNO S: Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimi-crob. Agents Chemother. (2000) 44:1728–1730.
   PubMed Web of Science ®Google Scholar
• PETRINI B, CHRISTENSSON B, CHRYSSANTHOU E, EDEBO L, LARSSON L: [Advances in the diagnosis of mycoses. New tests detect Candida infections]. Lakartidningen (1998) 95:738–742.
   PubMedGoogle Scholar
• LEUNG D, ABBENANTE G, FAIRLIE DP: Protease inhibi-tors: current status and future prospects. J. Med. Chem. (2000) 43:305–341.
   PubMed Web of Science ®Google Scholar
• GUJJAR PR, FINUCANE M, LARSEN B: The effect of estradiol on Candida albicans growth. Ann. Clin. Lab. Sci. (1997) 27:151–156.
   PubMed Web of Science ®Google Scholar
• WHITES, LARSEN B: Candida albkans morphogenesis is Influenced by estrogen. Cell. Mol. Life. Sci. (1997) 53:744–749.
   PubMed Web of Science ®Google Scholar
• ••Discussion of the role of steroids in Candida virulence.
   Google Scholar
• ESSMANN M, LARSEN B: Protective effect of the selective estrogen receptor modulator LY117018 on rat vaginal Candida albicans colonization. Gynecol. Obstet. Invest. (2000) 49:57–61.
   PubMed Web of Science ®Google Scholar